Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
53.18 USD | -1.77% |
|
+2.03% | -27.00% |
07:50am | Bio-Techne's Simple Western? Technology Utilized in Recent Fda Approval of Zevaskyn Cell-Based Gene Therapy | CI |
07-09 | TD Cowen Initiates Bio-Techne at Buy With $65 Price Target | MT |
Fiscal Period: June | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.82 | 7.17 | 8.21 | 7.12 | 5.74 | |||||
Return on Total Capital | 5.36 | 8.03 | 9.29 | 7.9 | 6.24 | |||||
Return On Equity % | 18.01 | 9.46 | 16.08 | 15.57 | 8.33 | |||||
Return on Common Equity | 17.99 | 9.53 | 16.66 | 15.55 | 8.33 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 65.41 | 68.14 | 68.57 | 67.76 | 66.47 | |||||
SG&A Margin | 36.18 | 34.12 | 33.6 | 34.89 | 36.97 | |||||
EBITDA Margin % | 26.94 | 31.94 | 32.56 | 30.27 | 26.78 | |||||
EBITA Margin % | 23.98 | 29.49 | 30.02 | 27.56 | 23.9 | |||||
EBIT Margin % | 20.41 | 26.43 | 27.09 | 24.73 | 21.16 | |||||
Income From Continuing Operations Margin % | 31.04 | 14.99 | 23.8 | 25.11 | 14.5 | |||||
Net Income Margin % | 31.04 | 15.08 | 24.61 | 25.1 | 14.5 | |||||
Net Avail. For Common Margin % | 31.01 | 15.07 | 24.6 | 25.09 | 14.5 | |||||
Normalized Net Income Margin | 11.23 | 15.22 | 17.17 | 14.96 | 12.11 | |||||
Levered Free Cash Flow Margin | 18.84 | 27.12 | 20.53 | 16.41 | 18.5 | |||||
Unlevered Free Cash Flow Margin | 20.47 | 28.06 | 21.17 | 17.02 | 19.35 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.38 | 0.43 | 0.49 | 0.46 | 0.43 | |||||
Fixed Assets Turnover | 3.67 | 3.51 | 3.88 | 3.71 | 3.48 | |||||
Receivables Turnover (Average Receivables) | 5.68 | 6.95 | 6.5 | 5.5 | 5.04 | |||||
Inventory Turnover (Average Inventory) | 2.63 | 2.7 | 2.7 | 2.34 | 2.21 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.88 | 3.35 | 3.44 | 4.84 | 3.87 | |||||
Quick Ratio | 3.69 | 2.48 | 2.51 | 3.29 | 2.47 | |||||
Operating Cash Flow to Current Liabilities | 1.92 | 2.31 | 1.85 | 1.98 | 1.88 | |||||
Days Sales Outstanding (Average Receivables) | 64.41 | 52.52 | 56.11 | 66.31 | 72.61 | |||||
Days Outstanding Inventory (Average Inventory) | 139.1 | 135.3 | 135.43 | 155.75 | 165.46 | |||||
Average Days Payable Outstanding | 26.88 | 30.87 | 31.04 | 27.37 | 29.36 | |||||
Cash Conversion Cycle (Average Days) | 176.63 | 156.94 | 160.5 | 194.68 | 208.71 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 32.64 | 27.3 | 19.19 | 23.14 | 20.28 | |||||
Total Debt / Total Capital | 24.61 | 21.44 | 16.1 | 18.79 | 16.86 | |||||
LT Debt/Equity | 31.05 | 25.72 | 17.73 | 22.57 | 19.65 | |||||
Long-Term Debt / Total Capital | 23.41 | 20.2 | 14.87 | 18.33 | 16.34 | |||||
Total Liabilities / Total Assets | 31.88 | 30.57 | 25.88 | 25.47 | 23.49 | |||||
EBIT / Interest Expense | 7.85 | 17.64 | 26.48 | 25.07 | 15.59 | |||||
EBITDA / Interest Expense | 11.22 | 23.9 | 33.48 | 32.49 | 21.2 | |||||
(EBITDA - Capex) / Interest Expense | 8.53 | 20.72 | 29.51 | 29.08 | 17.2 | |||||
Total Debt / EBITDA | 2.09 | 1.29 | 0.86 | 1.25 | 1.26 | |||||
Net Debt / EBITDA | 0.84 | 0.59 | 0.21 | 0.69 | 0.8 | |||||
Total Debt / (EBITDA - Capex) | 2.75 | 1.48 | 0.98 | 1.4 | 1.55 | |||||
Net Debt / (EBITDA - Capex) | 1.1 | 0.68 | 0.24 | 0.77 | 0.99 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 3.46 | 26.04 | 18.75 | 2.81 | 1.97 | |||||
Gross Profit, 1 Yr. Growth % | 1.25 | 31.3 | 19.49 | 1.6 | 0.03 | |||||
EBITDA, 1 Yr. Growth % | 0.7 | 49.42 | 21.05 | 1.33 | -9.79 | |||||
EBITA, 1 Yr. Growth % | -0.48 | 55 | 21.21 | 0.55 | -11.57 | |||||
EBIT, 1 Yr. Growth % | -1.3 | 63.24 | 21.68 | 0.73 | -12.75 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 138.67 | -39.12 | 88.49 | 8.49 | -41.11 | |||||
Net Income, 1 Yr. Growth % | 138.67 | -38.76 | 93.75 | 4.86 | -41.07 | |||||
Normalized Net Income, 1 Yr. Growth % | 1.46 | 70.87 | 33.98 | -4 | -17.45 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 135.63 | -40.38 | 91.07 | 6.02 | -40.34 | |||||
Accounts Receivable, 1 Yr. Growth % | -10.86 | 18.65 | 33.82 | 12.3 | 10.49 | |||||
Inventory, 1 Yr. Growth % | 13.29 | 13.18 | 20.88 | 21.62 | 4.72 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 61.19 | 13.47 | 2.5 | 12.37 | 5.52 | |||||
Total Assets, 1 Yr. Growth % | 7.6 | 11.61 | 1.41 | 14.99 | 2.47 | |||||
Tangible Book Value, 1 Yr. Growth % | -193.06 | -23.77 | 234.96 | 60.6 | 5.36 | |||||
Common Equity, 1 Yr. Growth % | 18.5 | 13.16 | 8.88 | 15.56 | 5.2 | |||||
Cash From Operations, 1 Yr. Growth % | 12.99 | 71.61 | -7.64 | -21.79 | 17.53 | |||||
Capital Expenditures, 1 Yr. Growth % | 103.63 | -14.38 | 1.37 | -14.84 | 64.41 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -5.78 | 83.52 | -10.67 | -12.94 | 14.96 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -6.27 | 74.63 | -10.95 | -12.56 | 15.88 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 0 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 7.18 | 14.19 | 22.34 | 10.49 | 2.39 | |||||
Gross Profit, 2 Yr. CAGR % | 5.44 | 15.3 | 25.26 | 10.18 | 0.81 | |||||
EBITDA, 2 Yr. CAGR % | -0.89 | 22.67 | 34.49 | 6.62 | -4.39 | |||||
EBITA, 2 Yr. CAGR % | -2.18 | 24.2 | 36.89 | 5.93 | -5.71 | |||||
EBIT, 2 Yr. CAGR % | -3.96 | 26.93 | 40.94 | 5.74 | -6.25 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 34.82 | 20.54 | 7.12 | 43 | -20.07 | |||||
Net Income, 2 Yr. CAGR % | 34.82 | 20.89 | 8.92 | 42.54 | -21.39 | |||||
Normalized Net Income, 2 Yr. CAGR % | -6.92 | 31.67 | 51.31 | 8.28 | -10.98 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 32.6 | 18.53 | 6.73 | 42.23 | -20.47 | |||||
Accounts Receivable, 2 Yr. CAGR % | 0.93 | 2.84 | 26 | 22.58 | 11.39 | |||||
Inventory, 2 Yr. CAGR % | 9.74 | 13.24 | 16.97 | 21.25 | 12.85 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 30.7 | 35.24 | 7.85 | 7.32 | 8.89 | |||||
Total Assets, 2 Yr. CAGR % | 12.81 | 9.58 | 6.39 | 7.98 | 8.55 | |||||
Tangible Book Value, 2 Yr. CAGR % | 97.82 | -15.77 | 59.8 | 131.94 | 30.08 | |||||
Common Equity, 2 Yr. CAGR % | 13.14 | 15.8 | 11 | 12.17 | 10.26 | |||||
Cash From Operations, 2 Yr. CAGR % | 9.75 | 39.25 | 25.9 | -15.01 | -4.13 | |||||
Capital Expenditures, 2 Yr. CAGR % | 57.22 | 32.04 | -6.84 | -7.09 | 18.33 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 27.59 | 30.73 | 27.7 | -14.88 | 0.04 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 28.28 | 27.26 | 24.42 | -14.73 | 0.66 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 0 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 9.48 | 13.13 | 15.69 | 15.45 | 7.58 | |||||
Gross Profit, 3 Yr. CAGR % | 8.57 | 13.44 | 16.68 | 16.81 | 6.69 | |||||
EBITDA, 3 Yr. CAGR % | 2.21 | 13.64 | 22.12 | 20.02 | 0.84 | |||||
EBITA, 3 Yr. CAGR % | 1.24 | 14.04 | 23.09 | 20.93 | -0.26 | |||||
EBIT, 3 Yr. CAGR % | 0.3 | 14.62 | 25.16 | 23.08 | -0.82 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 44.44 | 3.43 | 39.91 | 7.57 | 6.39 | |||||
Net Income, 3 Yr. CAGR % | 44.44 | 3.63 | 41.48 | 7.55 | 6.18 | |||||
Normalized Net Income, 3 Yr. CAGR % | -1.96 | 13.97 | 32.43 | 27.04 | -1.08 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 42.06 | 1.59 | 38.98 | 6.55 | 6.47 | |||||
Accounts Receivable, 3 Yr. CAGR % | 1.6 | 6.52 | 12.27 | 21.26 | 18.41 | |||||
Inventory, 3 Yr. CAGR % | 19.7 | 10.88 | 15.73 | 18.5 | 15.47 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 22.48 | 24.68 | 23.31 | 9.34 | 6.72 | |||||
Total Assets, 3 Yr. CAGR % | 9.17 | 12.41 | 6.79 | 9.18 | 6.11 | |||||
Tangible Book Value, 3 Yr. CAGR % | 18.74 | 43.96 | 33.44 | 60.07 | 78.3 | |||||
Common Equity, 3 Yr. CAGR % | 13.3 | 13.14 | 13.44 | 12.5 | 9.8 | |||||
Cash From Operations, 3 Yr. CAGR % | 12.61 | 27.39 | 21.44 | 7.42 | -5.31 | |||||
Capital Expenditures, 3 Yr. CAGR % | 50.5 | 28.39 | 20.9 | -9.59 | 12.38 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -11.55 | 43.47 | 15.39 | 10.25 | -5.91 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -9.76 | 41.67 | 13.21 | 8.58 | -5.55 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 0 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.31 | 13.28 | 14.45 | 12.07 | 10.17 | |||||
Gross Profit, 5 Yr. CAGR % | 8.99 | 13.15 | 14.96 | 12.13 | 10.05 | |||||
EBITDA, 5 Yr. CAGR % | 1.34 | 9.32 | 14.07 | 11.17 | 9.45 | |||||
EBITA, 5 Yr. CAGR % | 0.22 | 9.17 | 14.22 | 11.09 | 9.25 | |||||
EBIT, 5 Yr. CAGR % | -1 | 9.16 | 14.92 | 11.46 | 9.93 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 16.31 | 5.97 | 28.16 | 17.74 | 11.84 | |||||
Net Income, 5 Yr. CAGR % | 16.31 | 6.09 | 29.02 | 17.73 | 11.84 | |||||
Normalized Net Income, 5 Yr. CAGR % | -3.35 | 7.81 | 16.63 | 12.17 | 11.42 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 15.03 | 4.38 | 26.71 | 16.29 | 11.2 | |||||
Accounts Receivable, 5 Yr. CAGR % | 11.84 | 9.25 | 10.74 | 12.67 | 11.92 | |||||
Inventory, 5 Yr. CAGR % | 15.78 | 15.38 | 18.6 | 14.92 | 14.57 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 13.86 | 16.31 | 16.41 | 17.43 | 17.32 | |||||
Total Assets, 5 Yr. CAGR % | 13.78 | 14.91 | 8.05 | 10.62 | 7.49 | |||||
Tangible Book Value, 5 Yr. CAGR % | -3.56 | -5.49 | 33.72 | 74.22 | 32.09 | |||||
Common Equity, 5 Yr. CAGR % | 10.28 | 12.19 | 12.38 | 12.75 | 12.16 | |||||
Cash From Operations, 5 Yr. CAGR % | 8.05 | 19.56 | 17.75 | 8.35 | 10.48 | |||||
Capital Expenditures, 5 Yr. CAGR % | 21.05 | 21.26 | 24.23 | 12.81 | 19.87 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 5.72 | 14.66 | 2.45 | 16.88 | 7.73 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 7.29 | 15.25 | 2.61 | 16.07 | 6.81 | |||||
Dividend Per Share, 5 Yr. CAGR % | 0 | 0 | 0 | 0 | 0 |
- Stock Market
- Equities
- TECH Stock
- Financials Bio-Techne Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition